Drug details

Bydureon Bcise (exenatide extended-release injectable suspension)

type of Antidiabetics, Glucagon-like Peptide-1 Agonists

Bydureon Bcise (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• nausea,
• vomiting,
• fever,
• unusual bleeding,
• dizziness,
• swelling,
• headache,
• sweating,
• trouble swallowing,
• little or no urination,
• painful or difficult urination,
• swelling in your feet or ankles,
• anxiety,
• irritability,
• pain,
• fast heart rate,
• hunger,
• yellowing of your skin or eyes (jaundice),
• shortness of breath
• severe ongoing nausea,
• warmth,
• hoarse voice,
• bruising,
• tiredness, and
• swelling in your neck or throat (enlarged thyroid),
• open wound or scab,
• skin changes where the injection was given,
• pain in your upper stomach spreading to your back,
• shakiness,

The following drugs are related to Bydureon Bcise, either as a replacement or used together:

• Brenzavvy (bexagliflozin tablets)
• Qternmet XR (dapagliflozin, saxagliptin, and metformin hydrochloride)